cabozantinib
1. Basic Product Identification
Name: Cabozantinib
Brand examples: Cabometyx, Cometriq
Class: Tyrosine kinase inhibitor (TKI), multi-targeted anticancer agent
ATC Code: L01EX07
Molecular Formula: C₂₈H₂₄FN₃O₅
Molecular Weight: 501.5 g/mol
Appearance: White to off-white solid crystalline powder
Solubility: Slightly soluble in aqueous media, soluble in organic solvents
Key Feature: Broad-spectrum kinase inhibitor (MET, VEGFR2, AXL)
2. Therapeutic Knowledge
Indications:
Advanced renal cell carcinoma (RCC)
Hepatocellular carcinoma (HCC)
Medullary thyroid cancer (MTC)
Therapeutic class:
Oncology targeted therapy
Clinical role:
Anti-angiogenic + anti-tumor proliferation agent
3. Mechanism of Action (MOA)
Cabozantinib inhibits multiple receptor tyrosine kinases:
Primary targets:
VEGFR2 → inhibits tumor angiogenesis
MET (HGFR) → blocks tumor growth and metastasis
AXL → reduces tumor resistance mechanisms
Result:
↓ Blood vessel formation
↓ Tumor cell proliferation
↓ Metastatic spread
Overcomes resistance to other TKIs
4. Pharmacokinetics (ADME)
Absorption
Oral bioavailability ~70–80%
Tmax: 3–4 hours
Distribution
Highly protein bound (~99.7%)
Metabolism
Hepatic metabolism:
CYP3A4 (major pathway)
Active metabolites present
Excretion
Feces (major route)
Urine (minor)
Half-life
~55–120 hours (long elimination)
5. Dosage & Administration
Standard dosing
60 mg once daily (RCC, HCC)
140 mg once daily (older MTC formulation)
Administration rules
Taken on empty stomach
No food intake 2 hours before/after
Dose reduction common due to toxicity
6. Formulation Knowledge
Dosage forms
Film-coated tablets (Cabometyx)
Capsules (older formulation)
Key excipients:
Microcrystalline cellulose
Lactose monohydrate
Hydroxypropyl cellulose
Magnesium stearate
Film coating polymers (HPMC, PEG)
Critical formulation aspect:
Poor solubility → requires particle size engineering
7. Raw Materials Knowledge
API: Cabozantinib (free base or malate salt)
Key intermediates:
Quinoline derivatives
Aniline-based heterocycles
Critical concerns:
Polymorphism control
Impurity control (genotoxic impurities risk)
8. Manufacturing Process Knowledge
API synthesis (high-level)
Multi-step organic synthesis:
Heterocyclic coupling reactions
Fluorination chemistry
Amide bond formation
Purification:
Recrystallization + chromatography
Formulation process:
Micronization (critical for dissolution)
Wet granulation or direct compression
Film coating for stability
Blending uniformity control
9. Analytical & QC Knowledge
Key tests:
Assay (HPLC)
Related substances (critical for oncology drugs)
Dissolution profile (biorelevant media)
Particle size distribution
Residual solvents (GC-MS)
Polymorphic form analysis (XRPD)
Content uniformity
Critical impurities:
Process-related heterocycles
Nitroso-amine risk (regulatory concern in TKIs)
10. Regulatory Knowledge
Approved by:
FDA, EMA, global oncology authorities
Regulatory classification:
Oral oncology small molecule (high scrutiny)
Requirements:
Full NDA/MAA dossier
Impurity genotoxicity assessment
Risk management plan (RMP)
11. Storage & Stability
Store at 20–25°C
Protect from:
Moisture
Light
Stability concerns:
Hydrolysis under humidity
Photodegradation (minor)
12. Packaging Knowledge
API:
Double-layer moisture-proof bags + fiber drums
Tablets:
Alu-Alu blister packaging (preferred)
Oncology packaging requirements:
Child-resistant containers
Tamper-evident seals
Stability-critical barrier packaging required
13. Safety & Toxicology
Common side effects:
Diarrhea
Fatigue
Hypertension
Hand-foot syndrome
Serious risks:
Hemorrhage
GI perforation
Hepatotoxicity
Contraindications:
Severe bleeding disorders
Monitoring required:
Liver enzymes
Blood pressure
14. Market & Commercial Knowledge
Oncology blockbuster TKI
Key competitors:
Sunitinib
Sorafenib
Lenvatinib
Key brands:
Cabometyx (tablet)
Market drivers:
Rising RCC incidence
Shift toward multi-targeted TKIs
High-value oncology segment
15. Intellectual Property (IP)
Developed by Exelixis (original innovator)
Strong patent portfolio:
Salt forms (malate)
Formulation patents
Combination therapies (nivolumab + cabozantinib)
Generic entry is highly regulated and delayed in many regions
16. Environmental & EHS Knowledge
Oncology API handling requirements:
Cytotoxic compound precautions
Waste management:
Dedicated incineration of contaminated materials
PPE requirements:
Full containment systems (OEB 4–5 handling level)
Environmental concern:
Active pharmaceutical waste toxicity
17. Export Documentation Knowledge
COA (Certificate of Analysis)
DMF (Drug Master File)
GMP certificate
Stability data (ICH Zone II–IV)
Impurity genotoxicity report
Occupational exposure banding (OEB documentation)
Oncology handling declarations
18. Business Development Knowledge
High-value oncology market
Key regions:
US, EU, Japan
Emerging oncology markets (India, China, LATAM)
Strategy:
Hospital oncology tenders
Partnership with oncology distributors
Combination therapy positioning (immune checkpoint inhibitors)
19. Advanced Technical Knowledge
Multi-kinase inhibition → resistance management key advantage
Low solubility → bioavailability challenges
Particle engineering critical for:
Dissolution rate control
Drug-drug interaction risk via CYP3A4 metabolism
Combination therapy synergy important in oncology protocols
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
Kinase inhibition modeling
Drug resistance prediction
Oncology patient stratification
Digital QA:
Impurity trend analytics
Real-time stability monitoring
Supply chain AI:
Oncology demand forecasting
Precision medicine integration:
Biomarker-based treatment selection
21. Sales Team Product Knowledge Checklist
Sales teams must know:
Mechanism: multi-kinase Austria inhibitor (MET/VEGFR/AXL)
Indications: RCC, HCC, MTC
Key safety issues: diarrhea, hypertension
Dosing rules: empty stomach requirement
Objections:
“Why high toxicity?” → explain oncology benefit-risk balance
“Why dose reductions?” → standard oncology practice
Competitor differentiation vs sunitinib/lenvatinib
22. Most Important Technical Documents
NDA/MAA dossiers
DMF (API)
Impurity qualification reports (genotoxicity studies)
Stability studies (ICH long-term + accelerated)
Dissolution similarity studies
Polymorphism characterization reports
Process validation reports
Cleaning validation (oncology containment)
Risk Management Plan (RMP)
23. Ultimate Pharma Product Mastery Summary
Cabozantinib is:
A high-value multi-target oncology tyrosine kinase inhibitor
Critical in renal, liver, and thyroid cancers
Technically complex due to:
Multi-kinase pharmacology
Solubility challenges
Strict oncology safety requirements
???? Competitive success depends on:
High-purity API synthesis
Controlled particle engineering
Regulatory excellence in oncology filings
Strong hospital oncology network penetration